Clinical trial · Interventional
Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine
Pilot Study to Test Uniformity of Transdermal Drug Delivery to the Breast Using Diclofenac Epolamine as a Model
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast. The drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. The drug amount that gathers in the breast, after application of a patch to the skin of the breast, will be measured and compared to the amount that is found in the breast when the patch is applied to the skin of the belly.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diclofenac epolamine patch | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Breast Group
- description
- Diclofenac epolamine patch applied to the breast
- interventionNames
- Drug: Diclofenac epolamine patch
- type
- EXPERIMENTAL
- label
- Abdomen Group
- description
- Diclofenac epolamine patch applied to the abdomen
- interventionNames
- Drug: Diclofenac epolamine patch
Primary outcomes (1)
- measure
- Compare concentrations of diclofenac epolamine patch when applied to breast vs. abdomen
- timeFrame
- after 3 days of treatment prior to surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Women between the ages of 18 and 80 years, undergoing total mastectomy for, with or without axillary surgery for diagnosis or prevention of breast cancer. * ECOG performance status less than 2. * Ability to understand and the willingness to sign a written informed consent. * Participants must have normal organ and marrow function Exclusion Criteria: * Prior history of ipsilateral breast radiotherapy. * Pregnant women and those who will be actively breast-feeding in the preoperative period will be excluded. * Inability to discontinue aspirin or warfarin use during the period of participation. * Known allergy to diclofenac epolamine, or aspirin, diclofenac (Cataflam, Voltaren), or another non-steroidal anti-inflammatory drug (NSAID). * Renal failure
References
Publications (0)
Data not yet available